Skip to content
2000
Volume 8, Issue 15
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The interdependency between genetic and epigenetic regulatory processes renders cancer therapeutics and translational clinic possible, even though they remain difficult tasks considering all the evidence supporting a central role of progenitor-stem cells as a causative source of cellular transformation. In contrast to genetic alterations, epigenetic processes are potentially reversible allowing a better action of complementary therapeutic compounds. Here I would first describe the plethora of interconnected epigenetic processes and targets to then discuss several therapeutic strategies on the basis of different compounds. I conclude that the advent of new and specific epigenetic target drugs will certainly contribute to better treatments and to the development of predictive protocols in a next future.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802608786141179
2008-10-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802608786141179
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test